Any solid tumor
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (4) | BRAF p.V600E | Any solid tumor | Dabrafenib, Trametinib | |
| FDA (2) | dMMR | Any solid tumor | Dostarlimab | |
| EMA (1) FDA (2) | v::NTRK1 | Any solid tumor | Entrectinib | |
| EMA (1) FDA (2) | v::NTRK2 | Any solid tumor | Entrectinib | |
| EMA (1) FDA (2) | v::NTRK3 | Any solid tumor | Entrectinib | |
| EMA (1) FDA (2) | v::NTRK1 | Any solid tumor | Larotrectinib | |
| EMA (1) FDA (2) | v::NTRK2 | Any solid tumor | Larotrectinib | |
| EMA (1) FDA (2) | v::NTRK3 | Any solid tumor | Larotrectinib | |
| FDA (2) | dMMR | Any solid tumor | Pembrolizumab | |
| FDA (2) | MSI-H | Any solid tumor | Pembrolizumab | |
| FDA (2) | TMB-H (>= 10 mutations / Mb) | Any solid tumor | Pembrolizumab | |
| EMA (1) FDA (2) | v::NTRK1 | Any solid tumor | Repotrectinib | |
| EMA (1) FDA (2) | v::NTRK2 | Any solid tumor | Repotrectinib | |
| EMA (1) FDA (2) | v::NTRK3 | Any solid tumor | Repotrectinib | |
| EMA (1) FDA (2) | v::RET | Any solid tumor | Selpercatinib | |
| EMA (1) FDA (2) | HER2-positive | Any solid tumor | Trastuzumab deruxtecan |